Cryptococcal meningitis is a fungal infection of the membranes surrounding the brain and spinal cord, caused by inhaling spores or dried yeast cells of the fungus Cryptococcus. It is one of the deadliest opportunistic infections in people living with HIV, responsible for roughly 15% of all AIDS-related deaths worldwide, and it kills an estimated 181,000 people each year. But the disease also strikes organ transplant recipients, people on immunosuppressive medications, and occasionally individuals with no known immune problems at all. Understanding how the fungus gets from the environment into the central nervous system, recognizing the warning signs early, and choosing the right treatment protocol can make the difference between survival and a fatality that was, in many cases, preventable.
Where the Fungus Lives and How You Breathe It In
Two main species cause nearly all human disease. Cryptococcus neoformans is found worldwide and thrives in soil contaminated with bird droppings, particularly pigeon guano. Cryptococcus gattii has historically been associated with tropical and subtropical climates and is linked to certain tree species, including eucalyptus. The geographic and environmental niches differ, but both species share the same route into the human body: inhalation.1PubMed Central. Environmental Status of Cryptococcus neoformans and Cryptococcus gattii in Colombia
When soil or droppings dry out, microscopic spores or desiccated yeast cells become airborne. A person breathes them in, and the fungus lands in the lungs, where the initial infection takes hold.2PubMed Central. Spores as infectious propagules of Cryptococcus neoformans In a person with a healthy immune system, white blood cells usually contain or eliminate the fungus before it goes any further. In someone whose immune defenses are weakened, however, the fungus can escape the lungs and spread through the bloodstream.
One point worth emphasizing: you do not catch cryptococcal meningitis from another person. It is purely an environmental infection. There is no reason to isolate a patient or worry about person-to-person transmission.
Who Is Most at Risk
The single biggest risk factor is advanced HIV infection, particularly when CD4 cell counts fall below 100 cells per microliter. In one US cohort, the median CD4 count among HIV-positive patients with cryptococcal meningitis was just 35 cells per microliter.3PubMed Central. Increased cryptococcal meningitis mortality among HIV negative, non-transplant patients: a single US center cohort study At that level of immune suppression, the body simply cannot mount an adequate defense against the fungus.
Outside of HIV, the next most common group is solid organ transplant recipients, who take potent immunosuppressive drugs to prevent rejection. Beyond transplant patients, a range of other conditions and medications raise risk:
- Glucocorticoid therapy: long-term steroid use suppresses the immune response broadly.
- Sarcoidosis: this inflammatory disease can impair immune function on its own and often requires steroid treatment.
- Idiopathic CD4 lymphopenia: a low CD4 count without HIV infection.
- Biologic therapies: drugs such as infliximab, alemtuzumab, ibrutinib, and fingolimod have all been linked to cases of cryptococcal meningitis in case reports and small series.4Open Forum Infectious Diseases. Clinical Characteristics and Risk Factors for Cryptococcal Meningitis in Diverse Patient Populations in New York City
The disease occasionally appears in people with no identifiable immune deficiency. When it does, researchers increasingly suspect subtle immune defects that standard testing does not catch, a topic explored later in this article.
How the Fungus Gets Into the Brain
Cryptococcus starts as a lung infection, but it does not stay there in vulnerable hosts. The fungus enters the bloodstream and travels to the brain, where it must cross the blood-brain barrier, a tightly sealed layer of cells that normally keeps pathogens out of the central nervous system.5PubMed Central. Mechanisms of Pulmonary Escape and Dissemination by Cryptococcus neoformans
Research has identified several strategies the fungus uses to breach this barrier. It can pass directly through the cells lining brain blood vessels, squeeze between those cells, or hitch a ride inside immune cells that are themselves crossing into the brain, a strategy sometimes called the “Trojan horse” mechanism.6PubMed Central. The pathways and the mechanisms by which Cryptococcus enters the brain The fungus triggers changes in the host cell’s internal scaffolding to ease its own passage across the barrier.7PubMed Central. Cryptococcus neoformans activates RhoGTPase proteins followed by protein kinase C, focal adhesion kinase, and ezrin to promote traversal across the blood-brain barrier
An interesting wrinkle in the biology: the virulence factors that allow Cryptococcus to invade human tissue were not “designed” for that purpose. The fungus is a soil organism with no biological need for an animal host. Its thick capsule, melanin production, and ability to grow at body temperature are traits that evolved for surviving environmental stresses like predation by amoebae, UV radiation, and desiccation. They just happen to double as weapons against the human immune system.8Taylor & Francis Online / Virulence. Pathogenicity and virulence of Cryptococcus neoformans from an environmental perspective
Symptoms and How They Develop
Cryptococcal meningitis usually comes on gradually. Unlike bacterial meningitis, which can go from first symptom to life-threatening in hours, the cryptococcal form typically unfolds over days to weeks. In a large retrospective study of 335 HIV-positive patients in India, about 72% presented within 30 days of their first symptom, with the range spanning from one day to four months.9Neurology India. Cryptococcal meningitis
The hallmark symptom is a severe, persistent headache that worsens over time and interferes with daily functioning. In that same study, 96% of patients reported headache as their dominant complaint. Fever accompanied the headache in about 79% of cases, though fever is absent in a substantial minority. Other common symptoms include nausea and vomiting, neck stiffness, sensitivity to light, and confusion or altered mental status. Some patients develop brief visual disturbances caused by rising pressure inside the skull.
The presentation can differ depending on immune status. In a US cohort, HIV-negative, non-transplant patients were significantly older and more likely to present with altered mental status compared to HIV-positive patients.3PubMed Central. Increased cryptococcal meningitis mortality among HIV negative, non-transplant patients: a single US center cohort study The slow onset can make the diagnosis easy to miss initially, especially if a clinician is not thinking about fungal causes of meningitis.
Diagnosis
Diagnosing cryptococcal meningitis requires a lumbar puncture to collect cerebrospinal fluid. Testing that fluid for cryptococcal antigen using a lateral flow assay is now the preferred rapid test, with sensitivity above 99% and specificity above 99% in a large multicenter validation.10Emerging Infectious Diseases. Multisite Validation of Cryptococcal Antigen Lateral Flow Assay and Quantification by Laser Thermal Contrast The test produces results in about ten minutes and requires no lab equipment, making it usable in low-resource settings where the disease burden is heaviest.
Older diagnostic methods are less reliable. India ink staining, which allows the fungus to be seen under a microscope, misses roughly one in seven cases overall and performs much worse when the fungal burden in the spinal fluid is low, catching only about 42% of cases with lower organism counts.10Emerging Infectious Diseases. Multisite Validation of Cryptococcal Antigen Lateral Flow Assay and Quantification by Laser Thermal Contrast Culture of the cerebrospinal fluid remains the gold standard for species confirmation but takes days to grow. In practice, a positive antigen test is enough to start treatment immediately.
Treatment
Treatment follows three phases: induction, consolidation, and maintenance. The induction phase is the most intensive and has undergone a major shift in recent years thanks to the AMBITION trial, a landmark study that changed global guidelines.
The newer protocol uses a single high dose of liposomal amphotericin B (given intravenously at 10 mg per kilogram of body weight on day one) combined with 14 days of oral fluconazole and flucytosine.11JAMA Network Open. Single-Dose Liposomal Amphotericin Plus Fluconazole and Flucytosine for Cryptococcal Meningitis at a US Public Hospital This simplified approach was shown to be as effective as older regimens that required daily intravenous amphotericin infusions for one to two weeks, which are hard on the kidneys and require close monitoring. In a real-world implementation study in Uganda, ten-week survival with the single-dose protocol was about 69%, comparable to the roughly 72% seen in the original trial’s intervention arm.12PubMed Central. Implementation of Single High-dose Liposomal Amphotericin B Based Induction Therapy for Treatment of HIV-associated Cryptococcal Meningitis in Uganda: A Comparative Prospective Cohort Study
For HIV-negative patients, the evidence base is thinner, and treatment tends to follow a more traditional course of daily amphotericin B. Adding flucytosine to amphotericin appears to improve outcomes in this group as well: a nationwide observational study found that two-week mortality dropped from about 11% with amphotericin alone to about 6% when flucytosine was added.13PubMed. Comparison of liposomal amphotericin B alone and in combination with flucytosine in the treatment of non-HIV Cryptococcal meningitis
After induction, patients move to consolidation therapy with high-dose fluconazole for about eight weeks, followed by a longer maintenance phase at a lower dose. In HIV-positive patients, maintenance fluconazole continues until the immune system has recovered enough on antiretroviral therapy to safely stop it.14Medical Mycology Case Reports. Emerging fluconazole resistance: Implications for the management of cryptococcal meningitis
Managing Raised Intracranial Pressure
One of the most dangerous aspects of cryptococcal meningitis is the buildup of pressure inside the skull. The fungus and the body’s inflammatory response can obstruct the normal flow and absorption of cerebrospinal fluid, causing headaches, vomiting, vision loss, and, if unchecked, brain herniation and death. Managing this pressure is as important as the antifungal drugs themselves.
The primary tool is therapeutic lumbar puncture, where fluid is drained through a spinal needle to relieve pressure. Some patients need this done repeatedly. In an extreme published case, a single patient received 76 lumbar punctures over the course of one hospitalization to control persistently elevated pressure.15PubMed Central. Persistently elevated intracranial pressure in cryptococcal meningitis– 76 therapeutic lumbar punctures That is an outlier, but it illustrates how relentless the problem can be.
A large US study found that repeat lumbar punctures were associated with dramatically lower mortality across every patient group. Compared to patients who only received an initial diagnostic lumbar puncture, those who had additional therapeutic ones had a roughly 60% lower risk of death. The benefit held for people with HIV, transplant recipients, and patients without either risk factor.16PubMed Central. Lumbar puncture frequency and patient survival among persons hospitalized with cryptococcal meningitis in the United States Despite this evidence, repeat lumbar punctures remain underused in many settings, partly because they are uncomfortable for patients and labor-intensive for clinicians.
When to Start Antiretroviral Therapy in HIV-Positive Patients
For people diagnosed with both HIV and cryptococcal meningitis at the same time, a natural instinct would be to start antiretroviral therapy (ART) as quickly as possible to rebuild the immune system. The evidence says the opposite. Starting ART too soon after a cryptococcal meningitis diagnosis increases the risk of death.
A randomized trial in sub-Saharan Africa compared starting ART within one to two weeks of diagnosis versus deferring it to about five weeks. The group that started earlier had a 26-week mortality of 45%, compared to 30% in the deferred group. Most of the excess deaths occurred between weeks two and five.17PubMed Central. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis A Cochrane review pooling data from four trials confirmed the pattern: early ART initiation increased overall mortality compared to delayed initiation.18Cochrane Database of Systematic Reviews. Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis
The likely explanation involves immune reconstitution inflammatory syndrome, or IRIS: as the recovering immune system suddenly “wakes up” and detects fungal organisms still present in the brain, it launches a violent inflammatory response that can be more damaging than the infection itself. Current guidelines therefore recommend deferring ART until at least four to six weeks after starting antifungal treatment, once the fungal burden has been reduced and the acute infection stabilized.
Screening and Prevention in People Living With HIV
Because cryptococcal meningitis is so deadly and treatment so resource-intensive, the public health strategy in high-burden settings has shifted toward catching the infection before it reaches the brain. The approach relies on testing for cryptococcal antigen in the blood of HIV-positive people with low CD4 counts. A positive blood test indicates the fungus is circulating even before symptoms develop.
Pre-emptive fluconazole given to people who test positive for cryptococcal antigen but do not yet have meningitis has been shown to reduce the incidence of full-blown meningitis from about 20% to 5%.19PubMed Central. Cryptococcal Antigenemia in Advanced Human Immunodeficiency Virus Disease: Pathophysiology, Epidemiology, and Clinical Implications A prospective study in South Africa confirmed the approach: screening patients starting ART and treating antigen-positive individuals with fluconazole resulted in markedly fewer meningitis cases and deaths in the first year compared to historical cohorts that did not screen.20Clinical Infectious Diseases. Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study
The prevalence of circulating antigen among people with very low CD4 counts is substantial. In a screening study of asymptomatic outpatients with advanced HIV in Kinshasa, nearly 18% tested positive for serum cryptococcal antigen. Among those who consented to lumbar puncture, half already had detectable fungus in their spinal fluid despite having no symptoms of meningitis.21Scientific Reports. Screening for cryptococcal antigenemia and meningeal cryptococcosis, genetic characterization of Cryptococcus neoformans in asymptomatic patients with advanced HIV disease in Kinshasa, Democratic Republic of Congo Numbers like these make the case for routine screening hard to argue against.
The Global Burden and the Access Problem
Cryptococcal meningitis is heavily concentrated in sub-Saharan Africa, which accounts for about 73% of the estimated 223,000 annual cases worldwide and roughly 75% of the 181,000 annual deaths.22The Lancet Infectious Diseases. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis The death toll is driven not only by the severity of the disease but also by unequal access to the drugs needed to treat it.
Flucytosine, one of the key drugs in the most effective treatment regimens, has been unavailable or unaffordable in most of sub-Saharan Africa for decades. Without it, clinicians are forced to rely on less effective protocols, and ten-week mortality in Africa has ranged from 24% to above 60%, compared with 10% to 26% in well-resourced settings.23Journal of Antimicrobial Chemotherapy. Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal The drug has existed for over fifty years and is off patent, yet supply chain failures and the small market for antifungals in low-income countries have kept it out of reach. Recent international efforts to make flucytosine available in Africa have gained momentum, but the gap remains wide.
Long-Term Neurological Consequences
Surviving cryptococcal meningitis does not always mean a full recovery. The infection can leave lasting damage to the brain and cranial nerves, and the risk of neurological sequelae is substantial. In a review of pediatric cases, about 20% of children with a documented clinical outcome had neurological problems after treatment. The most frequent was visual impairment, affecting roughly 13% of children. Other sequelae included limb weakness, learning difficulties, hearing loss, and seizures.24PubMed Central. Neurological Sequelae After Paediatric Cryptococcal Meningitis
The species of Cryptococcus matters here. Children infected with C. gattii had a much higher rate of visual impairment, about 32%, compared to around 5% with C. neoformans.24PubMed Central. Neurological Sequelae After Paediatric Cryptococcal Meningitis C. gattii tends to cause a more inflammatory type of infection with larger fungal masses (called cryptococcomas) that can compress brain tissue and cranial nerves. While less data exist on long-term sequelae in adults, visual loss, cognitive problems, and hearing changes are recognized complications in all age groups.
When “Healthy” People Get Cryptococcal Meningitis
Occasionally, cryptococcal meningitis appears in someone who has no HIV, no transplant, no obvious immune suppression. These cases have puzzled clinicians for years. A growing body of research points to a hidden immune defect: autoantibodies that neutralize a signaling molecule called GM-CSF, which plays a key role in activating macrophages, the immune cells responsible for killing fungi.
Researchers identified these anti-GM-CSF autoantibodies in HIV-negative patients with cryptococcal meningitis who had no other apparent immune problems. The antibodies blocked GM-CSF from doing its job, effectively creating a blind spot in the immune system specific to the type of defense needed against Cryptococcus.25PubMed Central. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis Subsequent work suggested this may be a particular risk factor for C. gattii infection in otherwise immunocompetent individuals.26PubMed Central. Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients The finding has since been confirmed in patients from different parts of the world, including a report of three Colombian patients with disseminated cryptococcosis who all carried high levels of these neutralizing autoantibodies.27PubMed Central. Anti-GM-CSF Neutralizing Autoantibodies in Colombian Patients with Disseminated Cryptococcosis
This discovery matters practically: if you are diagnosed with cryptococcal meningitis and have no known immune deficiency, testing for anti-GM-CSF autoantibodies can identify the underlying vulnerability and guide long-term management, including awareness that other infections dependent on the same immune pathway could potentially occur.
Cryptococcosis in Animals
Humans are not the only species affected. Cryptococcosis is the most common systemic fungal disease in cats worldwide. Cats typically develop nasal disease first, with symptoms like sneezing, nasal discharge, and facial swelling, though the infection can progress to the brain or disseminate to the skin.28PubMed Central. Cryptococcosis in cats: ABCD guidelines on prevention and management Among wild and exotic animals, koalas and ferrets are especially susceptible and serve as important carriers of the fungus. Pulmonary and neurological disease predominates across all affected species, though the clinical signs can be vague enough to make diagnosis challenging in veterinary practice.29Medical Mycology. Cryptococcosis in domestic and wild animals: A review
Cats do not transmit the fungus to their owners. As with human cases, the source is always the environment. But a cat diagnosed with cryptococcosis in your household might prompt you to consider whether local soil or roosting sites have high fungal concentrations, which is worth knowing if anyone in the home is immunosuppressed.